Current Edition

antibody drugs

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …

Continue Reading →
Acceleron

Merck’s reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond …

Continue Reading →
clinical trial

Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that TG02 has passed the initial …

Continue Reading →
immuno-oncology

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the …

Continue Reading →